

May 2, 2022

To Our Valued Clients,

Effective May 2nd, GeneDx, formerly a subsidiary of BioReference, has been acquired by Sema4. At BioReference | GenPath, we remain committed to the physician community and patients we serve, and have been working to ensure a smooth transition of our hereditary cancer and molecular prenatal genetic services. We will continue to offer comprehensive hereditary cancer testing and prenatal genetic testing services, and you will receive the same level of quality service and experience through BioReference | GenPath.

This transaction allows BioReference | GenPath to focus efforts on our three core pillars of digitally-enabled, services-at-scale, and customized healthcare solutions. Additionally, the change will allow us to provide a clinically-focused and more streamlined hereditary cancer and prenatal genetic testing solutions.

While it is always a goal to keep service disruptions minimal, in the near future, there will be minimal changes to the ordering, reporting and billing processes related to hereditary cancer and molecular prenatal genetic services. If you have historically ordered these tests, your dedicated account executive will be setting up visits with you to discuss any enhancements or changes you can anticipate as we move forward.

As an evidenced-based and full reference specialty laboratory, BioReference | GenPath is proud to serve your practice and is committed to addressing your laboratory testing needs. We are excited about the forthcoming changes and to continually improve our standards of service, and we hope that this restructure is a positive modification toward our continued relationship as your laboratory provider.

If you have any immediate questions or concerns regarding these changes, please do not hesitate to call your dedicated account executive, or customer service to speak with a representative.

Best Regards,



Jon R. Cohen, MD
Executive Chairman
BioReference